Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Up 8.5% – Still a Buy?

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) shares rose 8.5% during trading on Wednesday . The company traded as high as $3.75 and last traded at $3.9810. 1,791,736 shares were traded during mid-day trading, a decline of 90% from the average daily volume of 17,579,939 shares. The stock had previously closed at $3.67.

Analyst Upgrades and Downgrades

RXRX has been the topic of several recent research reports. JPMorgan Chase & Co. reduced their price target on Recursion Pharmaceuticals from $11.00 to $10.00 and set an “overweight” rating on the stock in a research note on Thursday, April 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a report on Tuesday, April 21st. Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a research report on Thursday, May 7th. Wall Street Zen cut shares of Recursion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Finally, Morgan Stanley boosted their price objective on shares of Recursion Pharmaceuticals from $5.00 to $5.50 and gave the stock an “equal weight” rating in a research note on Thursday, May 14th. Two analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $8.10.

Recursion Pharmaceuticals Stock Up 1.0%

The company has a quick ratio of 5.47, a current ratio of 5.47 and a debt-to-equity ratio of 0.01. The company has a fifty day simple moving average of $3.30 and a 200 day simple moving average of $3.67. The firm has a market capitalization of $1.96 billion, a P/E ratio of -3.09 and a beta of 1.04.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.08. The firm had revenue of $6.47 million during the quarter, compared to the consensus estimate of $15.78 million. Recursion Pharmaceuticals had a negative return on equity of 54.33% and a negative net margin of 842.95%.The company’s revenue was down 56.8% on a year-over-year basis. During the same period last year, the company earned ($0.50) earnings per share. On average, equities analysts expect that Recursion Pharmaceuticals, Inc. will post -0.99 EPS for the current fiscal year.

Insider Activity

In other news, Director Blake Borgeson sold 30,000 shares of the company’s stock in a transaction that occurred on Tuesday, June 2nd. The shares were sold at an average price of $3.68, for a total value of $110,400.00. Following the transaction, the director owned 6,169,863 shares in the company, valued at approximately $22,705,095.84. This represents a 0.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Najat Khan sold 23,588 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $3.58, for a total transaction of $84,445.04. Following the completion of the transaction, the chief executive officer owned 2,175,796 shares in the company, valued at approximately $7,789,349.68. This represents a 1.07% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 121,937 shares of company stock worth $421,574 over the last three months. 6.65% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Recursion Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Bank of America Corp DE raised its stake in shares of Recursion Pharmaceuticals by 18.2% in the first quarter. Bank of America Corp DE now owns 2,496,831 shares of the company’s stock worth $7,665,000 after purchasing an additional 384,486 shares during the last quarter. Janus Henderson Group PLC boosted its position in shares of Recursion Pharmaceuticals by 59.4% during the first quarter. Janus Henderson Group PLC now owns 220,309 shares of the company’s stock valued at $675,000 after buying an additional 82,100 shares during the last quarter. California State Teachers Retirement System boosted its position in shares of Recursion Pharmaceuticals by 64.0% during the first quarter. California State Teachers Retirement System now owns 574,637 shares of the company’s stock valued at $1,764,000 after buying an additional 224,332 shares during the last quarter. The Manufacturers Life Insurance Company increased its holdings in Recursion Pharmaceuticals by 7.3% in the 1st quarter. The Manufacturers Life Insurance Company now owns 219,998 shares of the company’s stock worth $675,000 after buying an additional 15,049 shares in the last quarter. Finally, Themes Management Co LLC purchased a new position in Recursion Pharmaceuticals in the 1st quarter worth about $236,000. 89.06% of the stock is owned by institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.